MEDICAL ACTION INDUSTRIES INC - FORM 10-Q

Attached files

Attached files

Stock widget

Investing forum

MEDICAL ACTION INDUSTRIES INC Reports

Also read

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

file	filename
EXCEL - IDEA: XBRL DOCUMENT - MEDICAL ACTION INDUSTRIES INC	Financial_Report.xls
EX-31.1 - CEO CERTIFICATION - MEDICAL ACTION INDUSTRIES INC	d272193dex311.htm
EX-32.1 - CEO CERTIFICATION - MEDICAL ACTION INDUSTRIES INC	d272193dex321.htm
EX-31.2 - CFO CERTIFICATION - MEDICAL ACTION INDUSTRIES INC	d272193dex312.htm
EX-32.2 - CFO CERTIFICATION - MEDICAL ACTION INDUSTRIES INC	d272193dex322.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2011

COMMISSION FILE NUMBER 0-13251

MEDICAL ACTION INDUSTRIES INC.

(Exact name of registrant as specified in its charter)


DELAWARE		11-2421849
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

500 Expressway Drive South, Brentwood, NY 11717
(Address of principal executive offices)

Registrant’s telephone number, including area code:

(631) 231-4600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as described in Rule 12b-2 of the Exchange Act). Yes ¨ No x

16,390,628 shares of common stock are issued and outstanding as of February 3, 2012.

FORM 10-Q

CONTENTS


PART I.	FINANCIAL INFORMATION	Page No.

Item 1.	Condensed Consolidated Financial Statements	3
	Consolidated Balance Sheets at December 31, 2011 (Unaudited) and March 31, 2011	3
	Consolidated Statements of Operations for the Three and Nine Months Ended December 31, 2011 and 2010 (Unaudited)	4
	Consolidated Statement of Changes in Stockholders’ Equity for the Nine Months Ended December 31, 2011 (Unaudited)	5
	Consolidated Statements of Cash Flows for the Nine Months Ended December 31, 2011 and 2010 (Unaudited)	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	32

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	33
Item 1A.	Risk Factors	33
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	33
Item 3.	Defaults Upon Senior Securities	34
Item 4.	(Removed and Reserved)	34
Item 5.	Other Information	34
Item 6.	Exhibits	34
	Signatures	34

PART I. FINANCIAL INFORMATION

Item 1.

Condensed Consolidated Financial Statements

MEDICAL ACTION INDUSTRIES INC.

CONSOLIDATED BALANCE SHEETS

(dollars in thousands, except share and per share data)

		December 31,			December 31,
	December 31, 2011			March 31, 2011
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	1,003		$	1,691
Accounts receivable, less allowance for doubtful accounts of $818 at December 31, 2011 and $804 at March 31, 2011		35,728			32,330
Inventories, net		55,650			54,674
Prepaid expenses		2,258			1,702
Deferred income taxes		3,008			2,801
Prepaid income taxes		318			1,938
Other current assets		1,709			1,637

Total current assets		99,674			96,773

Property, plant and equipment, net		50,205			53,901
Goodwill, net		108,764			108,652
Other intangible assets, net		39,882			41,860
Other assets, net		2,940			3,319

Total assets	$	301,465		$	304,505


LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable	$	14,272		$	17,069
Accrued expenses		22,578			22,235
Current portion of capital lease obligation		121			92
Current portion of long-term debt		16,000			16,360

Total current liabilities		52,971			55,756
Deferred income taxes		27,956			27,956
Capital lease obligation, less current portion		13,690			13,790
Long-term debt, less current portion		55,470			58,776

Total liabilities		150,087			156,278

STOCKHOLDERS’ EQUITY:
Common stock—40,000,000 shares authorized, $.001 par value; issued and outstanding 16,390,628 shares at December 31, 2011 and 16,383,128 shares at March 31, 2011		16			16
Additional paid-in capital		34,308			33,799
Accumulated other comprehensive loss		(437	)		(437	)
Retained earnings		117,491			114,849

Total stockholders’ equity		151,378			148,227

Total liabilities and stockholders’ equity	$	301,465		$	304,505

The accompanying notes are an integral part of these condensed financial statements.

MEDICAL ACTION INDUSTRIES INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(dollars in thousands, except per share data)


	Three Months Ended December 31,				Nine Months Ended December 31,
	2011		2010		2011		2010
	(Unaudited)				(Unaudited)
Net sales	$	112,969	$	104,477	$	329,097	$	257,221
Cost of sales		95,824		86,055		278,294		211,415

Gross profit		17,145		18,422		50,803		45,806
Selling, general and administrative expenses		13,327		13,551		44,110		37,299

Operating income		3,818		4,871		6,693		8,507
Interest expense, net		1,174		1,116		3,421		1,742

Income before income taxes and extraordinary item		2,644		3,755		3,272		6,765
Income tax expense		819		1,451		1,070		2,600

Income before extraordinary item		1,825		2,304		2,202		4,165
Extraordinary gain (loss), net of applicable taxes (note 13)		—		—		440		(896	)

Net income	$	1,825	$	2,304	$	2,642	$	3,269


Per share basis:
Basic
Income before extraordinary item	$	0.11	$	0.14	$	0.13	$	0.25
Extraordinary gain (loss), net of applicable taxes		—		—		0.03		(0.05	)

Net income	$	0.11	$	0.14	$	0.16	$	0.20

Diluted
Income before extraordinary item	$	0.11	$	0.14	$	0.13	$	0.25
Extraordinary gain (loss), net of applicable taxes		—		—		0.03		(0.05	)

Net income	$	0.11	$	0.14	$	0.16	$	0.20

The accompanying notes are an integral part of these condensed financial statements.

MEDICAL ACTION INDUSTRIES INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

NINE MONTHS ENDED DECEMBER 31, 2011

(Unaudited)

(dollars in thousands, except share data)


	Common Stock				Additional Paid-In		Accumulated Other Comprehensive			Retained		Total Stockholders’
	Shares		Amount		Capital		Loss			Earnings		Equity
Balance at April 1, 2011		16,383,128	$	16	$	33,799	$	(437	)	$	114,849	$	148,227
Exercise of stock options		7,500		—		20							20
Amortization of deferred compensation						15							15
Tax benefit from vesting of restricted stock and exercise of stock options						19							19
Stock-based compensation						455							455
Net income											2,642		2,642

Balance at December 31, 2011		16,390,628	$	16	$	34,308	$	(437	)	$	117,491	$	151,378

The accompanying notes are an integral part of this condensed financial statement.

MEDICAL ACTION INDUSTRIES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands)


	Nine Months Ended December 31,
	2011			2010
	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	2,642		$	3,269
Adjustments to reconcile net income to net cash used in operating activities:
Extraordinary (gain) loss		(700	)		1,455
Depreciation		4,394			3,960
Amortization		3,264			2,321
Provision for doubtful accounts		39			9
Deferred income taxes		—			(45	)
Stock-based compensation		470			589
Excess tax liability from stock-based compensation		(207	)		—
Loss on disposal of property and equipment		—			20
Tax benefit from vesting of restricted stock and exercise of stock options		19			79
Changes in operating assets and liabilities:
Accounts receivable		(3,652	)		303
Inventories		(998	)		(16,372	)
Prepaid expenses and other current assets		72			423
Other assets		(907	)		(1,933	)
Accounts payable		(2,797	)		583
Prepaid income taxes		1,620			8
Accrued expenses		343			4,955

Net cash provided by (used in) operating activities		3,602			(376	)


CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase price and related acquisition costs		125			(62,525	)
Purchases of property, plant and equipment		(701	)		(2,914	)
Proceeds from sale of property and equipment		3			4

Net cash used in investing activities		(573	)		(65,435	)


CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit and long-term borrowings		74,217			155,380
Principal payments on revolving line of credit and long-term borrowings		(77,883	)		(90,428	)
Principal payments on capital lease obligation		(71	)		(20	)
Proceeds from exercise of stock options		20			152

Net cash (used in) provided by financing activities		(3,717	)		65,084


Net decrease in cash and cash equivalents		(688	)		(727	)
Cash and cash equivalents at beginning of period		1,691			5,641

Cash and cash equivalents at end of period	$	1,003		$	4,914


Supplemental disclosures:
Interest paid	$	2,347		$	1,189
Income taxes (refunded) paid	$	(491	)	$	1,947

The accompanying notes are an integral part of these condensed financial statements.

MEDICAL ACTION INDUSTRIES INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2011

(Unaudited)

Note 1. Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements of Medical Action Industries Inc. (“Medical Action” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q for quarterly reports under section 13 or 15(d) of the Securities Exchange Act of 1934. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine month period ended December 31, 2011 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2012. For further information, refer to the financial statements and footnotes thereto included in the Company’s 2011 Annual Report on Form 10-K.

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts of assets, liabilities, revenues and expenses reported in those financial statements as well as the disclosure of contingent assets and liabilities at the date of the consolidated financial statements. These judgments can be subjective and complex, and consequently, actual results could differ from those estimated. Significant estimates made by the Company include the allowance for doubtful accounts, inventory valuation, fair value of stock-based compensation, income taxes, valuation of long-lived assets, accrued sales incentives and rebate reserves. A summary of the Company’s significant accounting policies is identified in Note 1 “Organization and Summary of Significant Accounting Policies” of the Company’s 2011 Annual Report on Form 10-K. Users of financial information produced for interim periods are encouraged to refer to the notes contained in the 2011 Annual Report on Form 10-K when reviewing interim financial results. There have been no changes to the Company’s significant accounting policies or to the assumptions and estimates involved in applying these policies. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation. All dollar amounts presented in our notes to condensed consolidated financial statements are presented in thousands, except share and per share data.

Note 2. Summary of Significant Accounting Policies

The preparation of consolidated annual and quarterly financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. We have made a number of estimates and assumptions in the preparation of these consolidated financial statements. We can give no assurance that actual results will not differ from those estimates. Some of the more significant estimates include allowances for trade rebates and doubtful accounts, realizability of inventories, goodwill and other intangible assets, depreciation and amortization of long-lived assets, product liability, pensions and other postretirement benefits and environmental and litigation matters.

There have been no material changes to our significant accounting policies and estimates from the information provided in Note 1 “Organization and Summary of Significant Accounting Policies” of the notes to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011.

Note 3. Recently Issued Accounting Pronouncements

Revenue Arrangements with Multiple Deliverables

In October 2009, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2009-13, which will update Accounting Standard Codification (“ASC”) 605, Revenue Recognition, and changes the accounting for certain revenue arrangements. The new standard sets forth requirements that must be met for an entity to recognize revenue from the sale of a delivered item that is part of a multiple-element arrangement when other items have not yet been delivered and requires the allocation of arrangement consideration to each deliverable to be based on the relative selling price. ASU 2009-13 is effective prospectively for revenue arrangements entered into or materially modified in the fiscal years beginning on or after June 15, 2010, which for us was April 1, 2011. The adoption of this new accounting standard is not expected to have a material effect on the Company’s consolidated financial statements.

Goodwill Impairment Testing

In September 2011, the FASB issued authoritative guidance in ASC 350, Intangibles—Goodwill and Other, intended to simplify goodwill impairment testing. Entities will be allowed to perform a qualitative assessment on goodwill impairment to determine whether it is more likely than not (defined as having a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. This guidance is effective for goodwill impairment tests performed in interim and annual periods for fiscal years beginning after December 15, 2011, or the Company’s third quarter of fiscal 2012. The Company does not expect this guidance will have a material impact on its financial statements.

Note 4. Inventories

Inventories, which are stated at the lower of cost (determined by means of the first in, first out method) or market, consist of the following:


	December 31,		March 31,
	2011		2011
Finished Goods, net	$	28,651	$	28,922
Raw Materials, net		21,106		21,519
Work in Progress, net		5,893		4,233


Total Inventories, net	$	55,650	$	54,674

On a continuing basis, inventory quantities on hand are reviewed and an analysis of the provision for excess and obsolete inventory is performed based primarily on the Company’s sales history and anticipated future demand. The reserve for excess and obsolete inventory amounted to approximately $1,297 at December 31, 2011 and $1,415 at March 31, 2011.

Note 5. Business Acquisition

On August 27, 2010, the Company completed its acquisition of AVID Medical Inc. (“AVID”), a provider of custom procedure trays to the healthcare industry, in which the Company acquired the outstanding shares of common stock of AVID for $62,425.

The results of operations of this acquisition have been included in the consolidated financial statements from the date of acquisition. The purpose of this acquisition was to expand our product line offering into custom procedure trays to augment our existing product classes and expand our market presence in clinical care areas of acute care facilities and surgery centers throughout the country.

The following table summarizes the allocation of the final purchase price to the fair value of the assets acquired and liabilities assumed at the date of acquisition:


	Initial Purchase Price Allocation at August 27, 2010		Fiscal Year 2011 Adjustments			Preliminary Purchase Price Allocation at March 31, 2011		Fiscal Year 2012 Adjustments			Final Purchase Price Allocation at December 31, 2011
Cash	$	25	$	—		$	25	$	—		$	25
Accounts receivable, net		11,247		—			11,247		(215	)		11,032
Inventories		9,482		—			9,482		(22	)		9,460
Deferred tax assets		881		321			1,202		—			1,202
Other current assets		1,392		—			1,392		—			1,392
Property and equipment, net		16,071		—			16,071		—			16,071
Identifiable intangible assets:
Customer relationships		27,500		—			27,500		—			27,500
Trademarks		2,100		—			2,100		—			2,100
Goodwill		30,034		(2,081	)		27,953		112			28,065

Total assets acquired		98,732		(1,760	)		96,972		(125	)		96,847

Less :
Accounts payable and accrued expenses		10,624		(1,366	)		9,258		—			9,258
Deferred tax liabilities		11,692		(444	)		11,248		—			11,248
Debt, short-term and long-term		13,916		—			13,916		—			13,916

Total liabilities assumed		36,232		(1,810	)		34,422		—			34,422

Net assets acquired	$	62,500	$	50		$	62,550	$	(125	)	$	62,425

The following unaudited pro forma financial information for the three and nine months ended December 31, 2011 and 2010 represent the combined results of the Company’s operations as if the acquisition of AVID had occurred on April 1, 2010. The unaudited pro forma financial information does not necessarily reflect the results of operations that would have occurred had the Company constituted a single entity during such periods presented.


	Three Months ended				Nine Months ended
	December 31,				December 31,
	2011		2010		2011		2010
Net sales	$	112,969	$	104,477	$	329,097	$	312,960
Income before extraordinary item and income taxes	$	2,644	$	3,755	$	3,272	$	8,653
Net income	$	1,825	$	2,304	$	2,642	$	5,219
Net income per share-basic	$	0.11	$	0.14	$	0.16	$	0.32

Net income per share-diluted	$	0.11	$	0.14	$	0.16	$	0.32

Note 6. Related Party Transactions

As part of the assets and liabilities acquired as a result of the AVID acquisition, the Company assumed a capital lease obligation for the AVID facility located in Toano, VA. The facility, which includes a 185,000 square foot manufacturing and warehouse building and approximately 12 acres of land, is owned by Micpar Realty, LLC (“Micpar”). AVID’s founder, former CEO and principal shareholder, is a part owner of Micpar and subsequent to the acquisition of AVID was appointed to the Company’s board of directors and entered into an employment agreement with the Company on August 27, 2010, which expired in August 2011.

The gross and net book value of the capital lease is as follows:

		December 31,			December 31,
	December 31,			March 31,
	2011			2011
Capital lease, gross	$	11,409		$	11,409
Less: Accumulated amortization		(819	)		(358	)

Capital lease, net	$	10,590		$	11,051

The amortization expense associated with the capital lease is included in our selling, general and administrative expenses and amounted to $154 and $154 for the three months ended December 31, 2011 and 2010, respectively and $461 and $205 for the nine months ended December 31, 2011 and 2010, respectively.

As of December 31, 2011 the capital lease requires monthly payments of $122 with increases of 2% per annum. The lease contains provisions for an option to buy after three and five years and expires in March 2029. The effective rate on the capital lease obligation is 9.9%.

The following is a schedule by years of the future minimum lease payments under the capital lease as of December 31, 2011:


December 31,	Capital Lease Payments
2012	$	1,481
2013		1,511
2014		1,541
2015		1,572
2016		1,603
Thereafter		22,445

Total minimum lease payments		30,153
Less: Amounts representing interest		(16,342	)

Present value of minimum lease payments		13,811
Less: Current portion of capital lease obligation		(121	)

Long-term portion of capital lease obligation	$	13,690

Note 7. Goodwill and Intangible Assets

The change in the goodwill balance during the nine months ended December 31, 2011 is as follows:


Balance at April 1, 2011	$	108,652
AVID Acquisition (Note 5)		112

Balance at December 31, 2011	$	108,764

At December 31, 2011, other intangible assets consisted of the following:


	Gross Carrying Value		Accumulated Amortization		Total Net Book Value
Trademarks/Tradenames not subject to amortization	$	1,266	$	—	$	1,266
Trademarks subject to amortization (5 years)		2,100		560		1,540
Customer Relationships (20 years)		43,200		6,227		36,973
Intellectual Property (7 years)		400		297		103

Total Other Intangible Assets, net	$	46,966	$	7,084	$	39,882

At March 31, 2011, other intangible assets consisted of the following:


	Gross Carrying Value		Accumulated Amortization		Total Net Book Value
Trademarks/Tradenames not subject to amortization	$	1,266	$	—	$	1,266
Trademarks subject to amortization (5 years)		2,100		245		1,855
Customer Relationships (20 years)		43,200		4,607		38,593
Intellectual Property (7 years)		400		254		146

Total Other Intangible Assets, net	$	46,966	$	5,106	$	41,860

The Company recorded amortization expense related to the above amortizable intangible assets of $659 and $692 for the three months ended December 31, 2011 and 2010, respectively and $1,978 and $1,537 for the nine months ended December 31, 2011 and 2010, respectively. The estimated aggregate amortization expense for the cumulative five years ending December 31, 2016 amounts to $12,443.

Note 8. Credit Facilities and Long-Term Debt

Long-term debt consists of the following:


	December 31,			March 31,
	2011			2011
Revolving Credit Agreement (a)	$	11,470		$	2,136
Term Loan (a)		60,000			72,000
Industrial Revenue Bond (b)		—			1,000

Total debt	$	71,470		$	75,136
Less: current portion		(16,000	)		(16,360	)

Total long-term debt	$	55,470		$	58,776

(a) On October 17, 2006, the Company entered into a credit agreement with certain lenders and a bank acting as administration agent for the lenders (the “Prior Credit Agreement”). On August 27, 2010, the Company agreed to amend and restate the Prior Credit Agreement in its entirety and enter into an Amended and Restated Credit Agreement (the “Credit Agreement”) that provides for total borrowings of up to $110,000, consisting of (i) a secured term loan with a principal amount of $80,000 and (ii) a revolving credit facility, which amounts may be borrowed, repaid and re-borrowed up to $30,000. The Credit Agreement was amended as of June 28, 2011 to adjust certain covenants and financial ratios.

The term loan was used by the Company to repay an existing term loan provided for in the Prior Credit Agreement and to fund the acquisition of AVID. The revolving credit facility, which expires August 27, 2014, will be used to finance the working capital needs and general corporate purposes of the Company and its subsidiaries and for permitted acquisitions. Principal payments on the term loan are due and payable in 16 consecutive quarterly installments of $4,000 on the last day of each March, June, September and December thereafter, with the final payment due on August 27, 2015. Both the term loan and revolving credit facility bear interest as established by the Credit Agreement. The average interest rate on the term loan approximated 3.51% and 2.98%, during the nine months ended December 31, 2011 and 2010, respectively, and the average interest rate on the revolving credit facility approximated 5.52% and 4.43%, during the nine months ended December 31, 2011 and 2010, respectively. The Company’s availability under the revolving credit facility amounts to $18,530 as of December 31, 2011.

Borrowings under this agreement are collateralized by substantially all the assets of the Company, and the agreement contains certain restrictive covenants, which, among other matters, impose limitations with respect to the incurrence of liens, guarantees, mergers, acquisitions, capital expenditures, specified sales of assets and prohibits the payment of dividends. The Company is also required to maintain various financial ratios which are measured quarterly. As of December 31, 2011, the Company is in compliance with all such covenants and financial ratios.

(b) Amounts payable represent principal payments due in connection with the issuance and sale by The Buncombe County Industrial Facilities and Pollution Control Financing Authority of its $5,500 Industrial Development Revenue Bonds (Medical Action Industries Inc. Project), Series 1997 (the “Bonds”). In July 2011, the company elected to pay off the remaining principal of $910 and $1 in interest.

Note 9. Stock-Based Compensation Plans

The Company has various stock-based compensation plans, which are more fully described in Note 11 “Stockholders’ Equity and Stock Plans” of the notes to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended March 31, 2011.

The Company recognized stock-based compensation (exclusive of deferred tax benefits) for awards granted under the Company’s Stock Option Plans in the following line items in the Consolidated Statements of Operations:


	Three Months Ended December 31,				Nine Months Ended December 31,
	2011		2010		2011		2010
Cost of sales	$	8	$	35	$	34	$	103
Selling, general and administrative expenses		132		162		436		486

Stock-based compensation expense before income tax benefits	$	140	$	197	$	470	$	589

Net income was impacted by $97 (after tax) and $313 (after tax) or $.01 and $.02 per diluted share in stock-based compensation expense for the three and nine months ended December 31, 2011 and $121 (after tax) and $362 (after tax) or $0.01 and $0.02 per diluted share in stock-based compensation expense for the three and nine months ended December 31, 2010.

No stock options were granted to employees or members of the Company’s board of directors during the nine months ended December 31, 2011.

The Company granted 215,000 stock options to employees during the nine months ended December 31, 2010, which vest 25% during the nine months ended December 31, 2012, 25% during the nine months ended December 31, 2013 and 50% during the nine months ended December 31, 2014, expire 10 years from date of grant (during the nine months ended December 31, 2020), have a weighted average exercise price equal to $11.89, have a weighted average remaining contractual term of 8.4 years and weighted average grant date fair value of $6.60 per share determined based upon a Black-Scholes valuation model (refer to the table below for assumptions used to determine fair value). In addition to the above employee stock option grants, the Company granted 30,000 stock options to members of the Company’s board of directors during the nine months ended December 31, 2010, which became fully vested upon issuance, have a weighted average exercise price equal to $8.99, have a weighted average remaining contractual term of 8.6 years and weighted average grant date fair value of $5.04 per share determined based upon a Black-Scholes valuation model (refer to the table below for assumptions used to determine fair value).

The fair value of stock options on the date of grant, and the assumptions used to estimate the fair value of the stock options granted during the respective periods using the Black-Scholes option valuation model were as follows:

Three Months Ended
December 31,

Nine Months Ended
December 31,

2011

2010

2011

2010

Dividend yield

n/a

0.0

Weighted-average expected volatility

n/a

60.3

Risk-free interest rate

n/a

3.2

Expected life of options (in years)

n/a

5.3

Fair value of options granted

n/a

6.40

The following is a summary of restricted stock activity in our 1994 Stock Incentive Plan for the nine months ended December 31, 2011:


	Shares			Weighted Average Grant Price
Non-Vested at April 1, 2011		7,967		$	12.74
Granted		—		$	—
Vested		(467	)	$	15.31
Forfeited		—		$	—


Non-Vested at December 31, 2011		7,500		$	12.58

Grants of restricted stock are common stock awards granted to recipients with specified vesting provisions. The restricted stock issued vests based upon the recipients continued service over time (five-year vesting period). The Company estimates the fair value of restricted stock based on the Company’s closing stock price on the date of grant.

The following is a summary of the changes in outstanding options for all of the Company’s plans during the nine months ended December 31, 2011:


	Options			Weighted Average Exercise Price		Remaining Weighted Average Contract Life (Years)		Aggregate Intrinsic Value
Outstanding at April 1, 2011		1,328,937		$	12.54		6.1	$	46
Granted		—			—
Exercised		(7,500	)		2.67
Forfeited		—			—

Outstanding at December 31, 2011		1,321,437		$	12.60		5.4	$	—


Options exercisable at December 31, 2011		937,904		$	13.15		4.3	$	—

The total intrinsic value of options exercised during the nine months ended December 31, 2011 and 2010 was $47 and $199, respectively. As of December 31, 2011, there was approximately $2,347 of total ASC 718, Compensation-Stock Compensation unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Company’s plans. Such cost is expected to be recognized over a period of 2.5 years.

The following is a summary of the changes in non-vested stock options for the nine months ended December 31, 2011:


	Options			Weighted Average Grant Date Fair Value
Non-vested at April 1, 2011		501,625		$	6.13
Granted		—		$	—
Forfeited		—		$	—
Vested		(118,092	)	$	6.16


Non-vested at December 31, 2011		383,533		$	6.12

Note 10. Income Taxes

The Company’s provision for income taxes consists of U.S. state and local taxes in amounts necessary to align the Company’s year-to-date provision for income taxes with the effective tax rate that the Company expects to achieve for the full year. The Company’s annual effective tax rate for fiscal 2012 is estimated to be 38.6% (which includes U.S., state and local taxes) based upon the Company’s anticipated earnings.

For the nine months ended December 31, 2011 the Company recorded a provision for income taxes of $1,330 (including tax expense of $260 relating to an extraordinary gain), which consisted of U.S., state and local, as well as discrete items that resulted in a net benefit of $202 related to tax return to provision adjustments. For the nine months ended December 31, 2010, the Company recorded a provision for income taxes of $2,041 (including tax benefit of $559 relating to an extraordinary loss) which consisted of U.S., state and local taxes.

In accordance with the provisions of ASC 740, Income Taxes, we recognize in our financial statements only those tax positions that meet the more-likely-than-not-recognition threshold. We establish tax reserves for uncertain tax positions that do not meet this threshold. Interest and penalties associated with income tax matters are included in the provision for income taxes in our consolidated statements of operations. Our accrual for interest and penalties was $21 upon adoption of ASC 740 and at December 31, 2011.

Note 11. Earnings Per Share

Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common shares. Diluted earnings per share are based on the weighted average number of common and potential common shares outstanding. The calculation takes into account the shares that may be issued upon exercise of stock options, reduced by the

shares that may be repurchased with the funds received from the exercise, based on the average prices during the periods. Excluded from the calculation of earnings per share are options to purchase 1,321,437 shares for the three and nine months ended December 31, 2011 and 1,203,089 and 1,091,093 for the three and nine months ended December 31, 2010, as their inclusion would not have been dilutive.

The following is a reconciliation of the numerator and denominator of the basic and diluted net earnings per share computations for the three and nine months ended December 31, 2011 and 2010, respectively.


	Three Months Ended December 31,				Nine Months Ended December 31,
	2011		2010		2011		2010
Numerator :
Income before extraordinary item	$	1,825	$	2,304	$	2,202	$	4,165
Extraordinary gain (loss), net of applicable taxes (note 13)		—		—		440		(896	)

Net income for basic and diluted earnings per share	$	1,825	$	2,304	$	2,642	$	3,269


Denominator :
Denominator for basic earnings per share—weighted average shares		16,390,628		16,350,916		16,390,572		16,346,615

Effect of dilutive securities:
Employee and director stock options		—		20,744		31		44,966

Denominator for diluted earnings per share—adjusted weighted average shares		16,390,628		16,371,660		16,390,603		16,391,581


Per share basis:
Basic
Income before extraordinary item	$	0.11	$	0.14	$	0.13	$	0.25
Extraordinary gain (loss), net of applicable taxes		—		—		0.03		(0.05	)

Net income	$	0.11	$	0.14	$	0.16	$	0.20


Diluted
Income before extraordinary item	$	0.11	$	0.14	$	0.13	$	0.25
Extraordinary gain (loss), net of applicable taxes		—		—		0.03		(0.05	)

Net income	$	0.11	$	0.14	$	0.16	$	0.20

Note 12. Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value:

Cash and Cash Equivalents

The carrying amount approximates fair value because of the short maturity of those instruments.

Accounts Receivable

The carrying amount of trade receivables reflects net recovery value and approximates fair value because of their short outstanding terms.

Accounts Payable

The carrying amount of trade payables approximates fair value because of their short outstanding terms.

Current Portion of Long-Term Debt

The carrying value of our current portion of long-term debt equals fair market value because the interest rate reflects current market rates.

Long-Term Debt

The fair value of our long-term debt is estimated based on quoted market prices or current rates offered to us for debt of the same remaining maturities.

The estimated fair values of our financial instruments at December 31, 2011 and March 31, 2011 are as follows:


	December 31, 2011
	Carrying Amount		Level 1		Level 2		Level 3
Cash and cash equivalents	$	1,003	$	1,003	$	—	$	—
Accounts receivable, net	$	35,728	$	35,728	$	—	$	—
Accounts payable	$	14,272	$	14,272	$	—	$	—
Current portion of long-term debt	$	16,000	$	16,000	$	—	$	—
Long-term debt	$	55,470	$	55,470	$	—	$	—

	March 31, 2011
	Carrying Amount		Level 1		Level 2		Level 3
Cash and cash equivalents	$	1,691	$	1,691	$	—	$	—
Accounts receivable, net	$	32,330	$	32,330	$	—	$	—
Accounts payable	$	17,069	$	17,069	$	—	$	—
Current portion of long-term debt	$	16,360	$	16,360	$	—	$	—
Long-term debt	$	58,776	$	58,776	$	—	$	—

Note 13. Extraordinary Gains and Losses

During the nine months ended December 31, 2011, the Company recorded an extraordinary gain of $440 (net of tax expense of $260) as a result of an insurance settlement relating to inventories damaged as a result of weather-related water damage.

During the nine months ended December 31, 2010, the Company incurred an extraordinary loss of $896 (net of tax benefit of $559) relating to inventories damaged as a result of weather-related water damage. The inventories damaged were predominantly patient bedside disposables and did not negatively impact the Company’s service levels with respect to this product class.

Note 14. Other Matters

The Company is involved in multiple product liability cases, which are covered by insurance. While the results of these lawsuits cannot be predicted with certainty, management does not expect that the ultimate liabilities, if any, will have a material adverse effect on the financial position or results of operations of the Company.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statement

This report on Form 10-Q contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include plans and objectives of management for future operations, including plans and objectives relating to the future economic performance and financial results of the Company. The forward-looking statements relate to (i) the expansion of the Company’s market share, (ii) the Company’s growth into new markets, (iii) the development of new products and product lines to appeal to the needs of the Company’s customers, (iv) the retention of the Company’s earnings for use in the operation and expansion of the Company’s business and (v) the ability of the Company to avoid information technology system failures which could disrupt the Company’s ability to function in the normal course of business by potentially causing delays or cancellation of customer orders, impeding the manufacture or shipment of products, or resulting in the unintentional disclosure of customer or Company information.

Important factors and risks that could cause actual results to differ materially from those referred to in the forward-looking statements include, but are not limited to, the effect of economic and market conditions, the impact of the consolidation throughout the healthcare supply chain, volatility of raw material costs, volatility in oil prices, foreign currency exchange rates, the impact of healthcare reform, opportunities for acquisitions and the Company’s ability to effectively integrate acquired companies, the ability of the Company to maintain its gross profit margins, the ability to obtain additional financing to expand the Company’s business, the failure of the Company to successfully compete with the Company’s competitors that have greater financial resources, the loss of key management personnel or the inability of the Company to attract and retain qualified personnel, the impact of current or pending legislation and regulation, as well as the risks described from time to time in the Company’s filings with the Securities and Exchange Commission, which include this report on Form 10-Q and our Annual Report on Form 10-K for the fiscal year ended March 31, 2011.

The forward-looking statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the actual results, performance and/or achievements of the Company to differ materially from any future results, performance or achievements, express or implied, by the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, and that in light of the significant uncertainties inherent in forward-looking statements; the inclusion of such statements should not be regarded as a representation by the Company or any other person that the objectives or plans of the Company will be achieved.

Overview

We manufacture and market single-use medical products used principally by acute care facilities within the United States. Our product lines are divided into two markets, Clinical Care and Patient Care. Our Clinical Care market includes custom procedure trays, minor procedure kits and trays, operating room disposables and sterilization products. Our Patient Care market includes patient bedside products, containment systems for medical waste and laboratory products.

Our market approach encompasses ongoing strategic relationships with group purchasing organizations (“GPO’s”), integrated delivery networks (“IDN’s”), acute care facilities, surgery centers, clinical decision makers and procurement managers within acute care facilities, national and regional distributors and other end users of our products. Over the previous two years we have implemented an internal structure to support a market presence which encompasses; (i) a marketing team comprised of product line managers for each of our key product categories, (ii) an Executive Healthcare Services team that directly maintains our relationship with GPO’s and IDN’s, (iii) regional managers who supervise both Clinical Care and Patient Care sales representatives and maintain relationships with larger acute care facilities and (iv) sales representatives which maintain a direct presence with the end users of our products and manage compliance levels on GPO and IDN contracts. While we view the end users of our products as the critical decision point driving our market penetration, approximately 67% of our products are sold through two national distributors.

Our growth strategy has included both acquisitions and expansion of existing product lines. On August 27, 2010, we acquired AVID Medical Inc. (“AVID”) which markets and assembles custom procedure trays. AVID’s net sales were $34,905 and $102,987 for the three and nine months ended December 31, 2011, respectively. We had previously made both custom and standard minor procedure kits and trays. The acquisition of AVID significantly expanded our product line offerings within the Clinical Care market, increased our sales team and provided opportunities to cross sell our existing product lines. We have supply agreements with substantially every major GPO and IDN in the country including Novation, Premier and MedAssets. A majority of the acute care facilities that we sell to belong to at least one GPO. The supply agreements we have been awarded through these GPO’s designate the Company as a sole-source or multi-source provider for substantially all of our product offerings. We consider our relationships with the GPO’s and IDN’s that we conduct business with to be valuable intangible assets. The supply agreements with GPO’s and IDN’s typically have no minimum purchase requirements and terms of one to three years that can be terminated on ninety days advance notice. While the acute care facilities associated with the GPO’s and IDN’s are not obligated to purchase our product offerings, many of these supply agreements have resulted in unit sales growth for the Company. We were recently recognized for performance excellence by the two largest GPO’s in the healthcare industry, Novation and Premier. Acute care facility orders purchased through our supply agreements with these two GPO’s accounted for $30,985 and $96,289 or 27% and 29% of our total net sales for the three and nine months ended December 31, 2011, respectively.

Over time we have increased revenues both organically and via acquisition. At this time we have focused our resources on increasing sales within existing product lines and continuing synergy initiatives associated with the AVID acquisition to drive organic sales growth.

We source our products from our four production facilities in the United States and from foreign suppliers, principally based in China. Our domestic production facilities and foreign suppliers have sufficient capacity to meet current product demand.

We conduct injection molding production and blown film production in our Gallaway, Tennessee and Clarksburg, West Virginia facilities, respectively. We conduct minor procedure kit and tray assembly operations and custom procedure tray assembly operations in our Arden, North Carolina and Toano, Virginia facilities, respectively.

The principal raw materials used in the production of our product lines include resin and cotton. Our production facilities consume approximately 45 million pounds of resin, namely polypropylene and polyethylene, per annum. Cotton is purchased by our foreign suppliers and converted into finished products, principally operating room towels and laparotomy sponges. We purchase finished goods that contain approximately 11 million pounds of cotton per annum.

The challenging economic environment of the past three years has negatively impacted hospital utilization, placed adverse economic pressure on acute care facilities and fostered volatility in commodity prices. These factors have impacted our revenues, average selling prices and gross profit. We have addressed these conditions by expanding our product lines, investing in our sales and marketing teams, managing our operating costs and differentiating ourselves in the market by emphasizing our ability to add value to our customers by improving their patient outcomes. We remain committed to being a trusted partner to our customers known for delivering innovative solutions to the healthcare community to improve the quality of care and enhancing patient experiences.

During the three months ended December 31, 2011 and 2010, we reported revenues of $112,969 and $104,477, respectively. Our net income and earnings per diluted share during the three months ended December 31, 2011 and 2010 were $1,825 or $0.11, and $2,304 or $0.14, respectively.

During the nine months ended December 31, 2011 and 2010, we reported revenues of $329,097 and $257,221, respectively. Our net income and earnings per diluted share during the nine months ended December 31, 2011 and 2010 were $2,642 or $0.16 and $3,269 or $0.20, respectively. Net income during the nine months ended December 31, 2011 included a pre-tax gain of $700 on an insurance settlement relating to inventories damaged as a result of weather-related water damage and net income for the nine months ended December 31, 2010 included a pre-tax loss of $1,455 relating to the aforementioned damaged inventories and one-time transaction costs of $1,335 related to the acquisition of AVID.

We assess goodwill, long-lived assets and certain identifiable intangibles at least annually for impairment as of the end of the fiscal third quarter, or more frequently if certain events or circumstances warrant. Impairment testing is performed in two steps; (i) we determine impairment by comparing the fair value of the Company with its carrying value, and (ii) if there is an impairment, we measure the amount of the impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. The impairment test for long-lived assets and other intangible assets encompasses calculating a fair value of such asset and comparing the fair value to its carrying value. If the carrying value exceeds the fair value, impairment is recorded.

In light of the decline in our stock price, we reviewed the impact of the change in our market capitalization on the fair value of the Company in conjunction with our annual impairment assessment. We assessed that the fair value of the Company was in excess of its carrying value by approximately 13% and concluded that there was no impairment.

Application of the goodwill impairment test requires judgment. Fair value is estimated using a discounted cash flow methodology. This requires significant judgments including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, the useful life over which cash flows will occur, and determination of our weighted average cost of capital. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment.

We will continue to monitor and evaluate the potential impact on our business and perform interim impairment testing if triggering events arise prior to future annual impairment testing. Accordingly, it is possible that we could recognize an impairment charge in the future with respect to goodwill and/or other intangible assets.

THREE MONTHS ENDED DECEMBER 31, 2011 COMPARED TO THREE MONTHS ENDED DECEMBER 31, 2010:

The following table sets forth certain operational data (in dollars and as a percentage of net sales) for the three months ended December 31, 2011 and 2010:


	December 31, 2011		Percent of Net Sales			December 31, 2010		Percent of Net Sales
Net Sales	$	112,969		100.0	%	$	104,477		100.0	%
Cost of Sales		95,824		84.8	%		86,055		82.4	%

Gross Profit		17,145		15.2	%		18,422		17.6	%
Selling, General and Administrative Expenses		13,327		11.8	%		13,551		13.0	%

Operating Income		3,818		3.4	%		4,871		4.7	%
Interest Expense, net		1,174		1.0	%		1,116		1.1	%

Income Before Income Taxes and Extraordinary Item		2,644		2.3	%		3,755		3.6	%
Income Tax Expense		819		0.7	%		1,451		1.4	%

Net Income	$	1,825		1.6	%	$	2,304		2.2	%

The following table sets forth net sales by market and their related changes due to price/mix and volume/mix for the three months ended December 31, 2011 and 2010:


	December 31, 2011			December 31, 2010			Increase (decrease) due to price / mix			Increase (decrease) due to volume / mix		Increase (decrease) compared to prior year
Clinical Care Market Sales	$	68,420		$	64,502		$	2,036		$	1,882	$	3,918
Patient Care Market Sales		46,497			42,635			(178	)		4,040		3,862
Sales Related Adjustments		(1,948	)		(2,660	)		(223	)		935		712

Total Net Sales	$	112,969		$	104,477		$	1,635		$	6,857	$	8,492

Net sales were $112,969 and $104,477 during the three months ended December 31, 2011 and 2010, respectively. The increase in net sales was comprised of an increase in unit sales in the amount of $6,857 and an increase in the average selling prices of our products in the amount of $1,635. The increase in unit sales was predominantly attributable to higher domestic market penetration within our patient bedside plastics, custom procedure trays, operating room and measurement and collection products. The increase in average selling prices resulted principally from price increases implemented on our operating room and custom procedure trays products.

Gross profit decreased $1,277 or 6.9% to $17,145 from $18,422 during the three months ended December 31, 2011 and 2010, respectively. Gross profit as a percentage of net sales was 15.2% during the three months ended December 31, 2011 and 17.6% during the three months ended December 31, 2010. The decline in gross profit was attributable to the mix of products sold, an increase in costs of raw materials resulting from rising global commodity prices and higher freight-out costs. These increased costs were partially offset by increases in pricing to our customers and improved productivity in our manufacturing facilities.

Resin-related product lines which include containment systems for medical waste, patient bedside plastics and measurement and collection products, represent approximately 37% of the Company’s revenues for the three months ended December 31, 2011. The primary raw material utilized in the manufacture of these products is plastic resin. We have experienced volatility in resin costs consistent with global market prices of oil and natural gas during the past several years. In any given year we may purchase approximately 45 million pounds of resin. Our gross profit during the three months ended December 31, 2011 as compared to the three months ended December 31, 2010 was unfavorably impacted by $1,655 due to higher resin prices.

During the three months ended December 31, 2011, we imported approximately $22,222 of finished goods and certain raw materials from overseas vendors, principally China. Our main imports are operating room products, which include operating room towels and laparotomy sponges, minor procedure kits and trays and surgical instruments used in our minor procedure kits and trays and certain containment products and patient bedside disposable products that we do not produce domestically. The products we have produced in China include cotton and plastic resin as raw materials.

in cotton prices, we have not seen a corresponding decline in the cost of our cotton products, which are primarily sourced from China-based vendors. The volume of cotton included in our products is estimated to be approximately 11 million pounds per annum. Our gross profit during the three months ended December 31, 2011 as compared to the three months ended December 31, 2010 was unfavorably impacted by $1,180 due to higher costs of products sourced from overseas vendors.

In response to the increase in material costs during fiscal 2011 we have implemented price increases on certain cotton and resin based products. We have been limited in our ability to pass all raw material price increases on to our customers. Due to competitive market conditions and indications that cotton prices will start to decline during the latter part of fiscal 2012, we have passed on price increases that we believe will be sustainable. Net sales during the three months ended December 31, 2011 include approximately $992 of price increases to our customers.

Selling, general and administrative expenses amounted to $13,328 and $13,551 during the three months ended December 31, 2011 and 2010, respectively. The decrease of $223 or 1.6% is primarily attributable to a decline in legal-related expenditures. Both the three months ended December 31, 2011 and 2010 benefitted from a reduction in the Company’s bonus accrual which was precipitated by the failure to meet certain operational performance objectives.

Distribution expenses, which are included in selling, general and administrative expenses, amounted to $1,706 and $1,777 during the three months ended December 31, 2011 and 2010, respectively. The decrease is primarily due to increased labor-related costs, principally overtime expenses. The Company does not classify any expenses as distribution related in our Toano, VA facility added in the AVID acquisition as we utilize a third-party logistics provider for that facility’s supply chain management functions. Such expenses are deemed to be freight-out and are included in cost of sales.

Interest expense amounted to $1,174 and $1,116 during the three months ended December 31, 2011 and 2010, respectively. The increase in interest expense was attributable to an increase in interest rates, resulting from an amendment made to our credit agreement in June 2011.

Income tax expense amounted to $819 and $1,451 during the three months ended December 31, 2011 and 2010, respectively. Income tax expense as a percent of income before income taxes was 31.0% and 38.6% during the three months ended December 31, 2011 and 2010, respectively. Income tax expense declined as a percent of income before income taxes as a result of a benefit from a tax return to provision adjustment.

NINE MONTHS ENDED DECEMBER 31, 2011 COMPARED TO NINE MONTHS ENDED DECEMBER 31, 2010:

The following table sets forth certain operational data (in dollars and as a percentage of net sales) for the nine months ended December 31, 2011 and 2010:


	December 31, 2011		Percent of Net Sales			December 31, 2010			Percent of Net Sales
Net Sales	$	329,097		100.0	%	$	257,221			100.0	%
Cost of Sales		278,294		84.6	%		211,415			82.2	%

Gross Profit		50,803		15.4	%		45,806			17.8	%
Selling, General and Administrative Expenses		44,110		13.4	%		37,299			14.5	%

Operating Income		6,693		2.0	%		8,507			3.3	%
Interest Expense, net		3,421		1.0	%		1,742			0.7	%

Income Before Income Taxes and Extraordinary Item		3,272		1.0	%		6,765			2.6	%
Income Tax Expense		1,070		0.3	%		2,600			1.0	%

Income Before Extraordinary Item		2,202		0.7	%		4,165			1.6	%
Extraordinary Gain (Loss) (net of applicable taxes)		440		0.1	%		(896	)		(0.3	%)

Net Income	$	2,642		0.8	%	$	3,269			1.3	%

The following table sets forth net sales by market and their related changes due to price/mix and volume/mix for the nine months ended December 31, 2011 and 2010:

		December 31,			December 31,			December 31,			December 31,			December 31,
	December 31, 2011			December 31, 2010			Increase (decrease) due to price / mix			Increase (decrease) due to volume / mix			Increase (decrease) compared to prior year
Clinical Care Market Sales	$	199,478		$	138,387		$	95		$	60,996		$	61,091
Patient Care Market Sales		135,372			125,633			(1,752	)		11,491			9,739
Sales Related Adjustments		(5,753	)		(6,799	)		1,224			(178	)		1,046

Total Net Sales	$	329,097		$	257,221		$	(433	)	$	72,309		$	71,876

Net sales were $329,097 and $257,221 during the nine months ended December 31, 2011 and 2010, respectively. The increase in net sales includes $55,745 in higher sales of custom procedure trays acquired through the AVID acquisition. Excluding the custom procedure tray products we experienced an overall increase in net sales during the nine months ended December 31, 2011 of $16,131. The increase in net sales, excluding custom procedure tray products, was comprised of an increase in unit sales in the amount of $15,484, which was partially offset by a decrease in the average selling price of our products in the amount of $392. The increase in unit sales was predominantly attributable to higher domestic market penetration within our patient bedside plastics, operating room, measurement and collection, protective apparel and containment systems for medical waste products. The decrease in average selling prices resulted principally from declining prices on our patient bedside plastics and minor procedure kits and tray products, which were partially offset by price increases implemented on our operating room products. These declines resulted principally from competitive pressures, the renewal of certain GPO supply agreements and a change in mix of products purchased by our customers.

Gross profit increased $4,997 or 10.9% to $50,803 from $45,806 during the nine months ended December 31, 2011 and 2010, respectively. Gross profit as a percentage of net sales was 15.4% during the nine months ended December 31, 2011 and 17.8% during the nine months ended December 31, 2010. Increased sales volume of $55,745 in sales of custom procedure trays acquired through the AVID acquisition contributed to the increase in gross profit. However, we experienced a decline in gross profit on our remaining product lines of $4,170 during the nine months ended December 31, 2011 when compared to the nine months ended December 31, 2010. The decline in gross profit was attributable to the mix of products sold, an increase in costs of raw materials resulting from rising global commodity prices and higher freight-out costs. These increased costs were partially offset by improved productivity in our manufacturing facilities.

Resin-related product lines which include containment systems for medical waste, patient bedside plastics and measurement and collection products represent approximately 37% of the Company’s revenues for the nine months ended December 31, 2011. The primary raw material utilized in the manufacture of these products is plastic resin. We have experienced volatility in resin costs consistent with global market prices of oil and natural gas during the past several years. In any given year we may purchase approximately 45 million pounds of resin. Our gross profit during the nine months ended December 31, 2011 as compared to the nine months ended December 31, 2010 was unfavorably impacted by $3,728 due to higher resin prices.

During the nine months ended December 31, 2011, we imported approximately $55,882 of finished goods and certain raw materials from overseas vendors, principally China. Our main imports are operating room products, which include operating room towels and laparotomy sponges, minor procedure kits and trays and surgical instruments used in our minor procedure kits and trays and certain containment products and patient bedside disposable products that we do not produce domestically. The products we have produced in China include cotton and plastic resin as raw materials.

The costs within the global market for cotton, while still volatile, have declined from their peak in March 2011. The Company does not directly purchase unfinished cotton and convert the material into finished goods. However, cotton is the primary raw material utilized in the production of our operating room towels and laparotomy sponges. Notwithstanding the decline in cotton prices, we have not seen a corresponding decline in the cost of our cotton products, which are primarily sourced from China-based vendors. The volume of cotton included in our products is estimated to be approximately 11 million pounds per annum. Our gross profit during the nine months ended December 31, 2011 as compared to the nine months ended December 31, 2010 was unfavorably impacted by $4,540 due to higher costs of products sourced from overseas vendors.

In response to the increase in material costs during fiscal 2011 we have implemented price increases on certain cotton and resin based products. We have been limited in our ability to pass all raw material price increases on to our customers. Due to competitive market conditions and indications that cotton prices will start to decline during the latter part of fiscal 2012, we have passed on price increases that we believe will be sustainable. Net sales during the nine months ended December 31, 2011 include approximately $3,503 of price increases to our customers.

Selling, general and administrative expenses amounted to $44,110 and $37,299 during the nine months ended December 31, 2011 and 2010, respectively. The increase of $6,811 or 18.3% is primarily attributable to selling, general and administrative expenses added as a result of the AVID acquisition. Included in our selling, general and administrative expenses were $259 in various recall-related expenses incurred during the nine months ended December 31, 2011. These recalls were for products manufactured by an outside vendor and utilized in some of our kits and trays. Typically, the Company is reimbursed for all recall-related expenses by our outside vendors. However, these expenses were associated with a vendor that has since ceased operations. The Company has submitted a claim for reimbursement of these expenses, however we cannot provide assurances that any portion of these expenses will be reimbursed. Selling, general and administrative expenses for the nine months ended December 31, 2010 included one-time transaction costs of $1,335 related to the acquisition of AVID. Both the nine months ended December 31, 2011 and 2010 benefitted from a reduction in the Company’s bonus accrual which was precipitated by the failure to meet certain operational performance objectives.

Distribution expenses, which are included in selling, general and administrative expenses, amounted to $5,515 and $5,330 during the nine months ended December 31, 2011 and 2010, respectively. The increase is primarily due to increased labor-related costs, principally overtime expenses. The Company does not classify any expenses as distribution related in our Toano, VA facility added in the AVID acquisition as we utilize a third-party logistics provider for that facility’s supply chain management functions. Such expenses are deemed to be freight-out and are included in cost of sales.

Interest expense amounted to $3,421 and $1,742 during the nine months ended December 31, 2011 and 2010, respectively. The increase in interest expense was attributable to a net increase in average principal loan balances outstanding and an increase in interest rates. The increase in interest rates resulted from an amendment made to our credit agreement in June 2011.

During the nine months ended December 31, 2010, the Company incurred an extraordinary pre-tax loss of $1,455 relating to inventories damaged as a result of weather-related water damage. The inventories damaged were predominantly patient bedside disposables and did not negatively impact the Company’s service levels with respect to this product line. During the nine months ended December 31, 2011, the Company negotiated a settlement with our insurance broker for reimbursement of these damaged inventories in the amount of $700. This reimbursement has been categorized as an extraordinary gain on our financial statements.

Income tax expense amounted to $1,330 and $2,041 (inclusive of the tax impact resulting from the aforementioned extraordinary items) during the nine months ended December 31, 2011 and 2010, respectively. Income tax expense as a percent of income before income taxes was 32.7% and 38.4% during the nine months ended December 31, 2011 and 2010, respectively.

Liquidity and Capital Resources

Cash Flows

Cash and cash equivalents changed as follows during the nine months ended December 31:

		$(65,435)			$(65,435)
	2011			2010
Cash provided by (used in) operating activities	$	3,602		$	(376	)
Cash used in investing activities	$	(573	)	$	(65,435	)
Cash (used in) provided by financing activities	$	(3,717	)	$	65,084
Decrease in cash and cash equivalents	$	(688	)	$	(727	)

Historically, the Company’s primary sources of liquidity and capital resources have included cash provided by operations and the use of available borrowing facilities while the primary uses of liquidity and capital resources have included acquisitions, capital expenditures and payments on debt.

Cash provided by operating activities during the nine months ended December 31, 2011 was primarily comprised of (i) income from operations of $2,642, (ii) depreciation of $4,394, (iii) amortization of $3,264 and (iv) a decrease in prepaid income taxes of $1,620. This was partially offset by increases in (i) accounts receivable of $3,652, (ii) inventories of $998 and (iii) other assets of $907 as well as a decrease in accounts payable of $2,797.

Cash used in investing activities during the nine months ended December 31, 2011 consisted of purchases of property, plant and equipment. The majority of these capital expenditures related to machinery and equipment for our injection molding facility located in Gallaway, Tennessee. The Company’s credit facilities contain certain covenants and restrictions, which include limitations on capital expenditures. During fiscal 2012, the Company is permitted under the terms of its Credit Agreement, to spend up to $10,000 on capital expenditures per annum.

Cash provided by financing activities during the nine months ended December 31, 2011 consisted primarily of $3,666 in net payments under our Credit Agreement. During the nine months ended December 31, 2011, the Company reduced its term loan by $12,000, which was partially offset by an increase of $9,334 on our revolving credit loan.

Financial Position

The following table sets forth certain liquidity and capital resources data for the periods indicated:

		December 31,		December 31,
	December 31,		March 31,
	2011		2011
	(Unaudited)
Cash and Cash Equivalents	$	1,003	$	1,691
Accounts Receivable, net	$	35,728	$	32,330
Days Sales Outstanding		26.6		21.7
Inventories, net	$	55,650	$	54,674
Inventory Turnover		5.9		6.0
Current Assets	$	99,674	$	96,773
Working Capital	$	46,703	$	41,017
Current Ratio		1.9		1.7
Total Borrowings	$	85,281	$	89,018
Stockholder’s Equity	$	151,378	$	148,227
Debt to Equity Ratio		0.56		0.60

The Company is committed to maintaining a strong financial position through maintaining sufficient levels of available liquidity, managing working capital and generating cash flows necessary to meet operating requirements. Total borrowings outstanding were $85,281 with a debt to equity ratio of 0.56 to 1.0 at December 31, 2011 as compared to $89,018 with a debt to equity ratio of 0.60 to 1.0 at March 31, 2011. Cash and cash equivalents at December 31, 2011 were $1,003 and the Company had $18,530 available for borrowing under its revolving credit loan.

Working capital at December 31, 2011 was $46,703 compared to $41,017 at March 31, 2011 and the current ratio at December 31, 2011 was 1.9 to 1.0 compared to 1.7 to 1.0 at March 31, 2011. The increase in working capital is primarily due to an increase in accounts receivable of $3,652 and inventories of $998 as well as a decline in accounts payable of $2,797. The increase in accounts receivable and decline in accounts payable are due to the timing of sales and payments to vendors occurring in the ordinary course of business.

Borrowing Arrangements

On October 17, 2006, Medical Action entered into a Credit Agreement (the “Prior Credit Agreement”), among the Company, as borrower, JPMorgan Chase Bank, N.A., as administrative agent and the lenders party thereto (the “Prior Lenders”) pursuant to which the Prior Lenders agreed to make certain extensions of credit to the Company. On August 27, 2010, the Company agreed to amend and restate the Prior Credit Agreement in its entirety and entered into an Amended and Restated Credit Agreement (the “Credit Agreement”), among the Company, as borrower, JPMorgan Chase, N.A., as administrative agent, Citibank, N.A., as syndication agent and HSBC Bank USA, N.A., Sovereign Bank and Wells Fargo Bank, N.A. as co-documentation agents and the other lenders party thereto (the “Lenders”). The Credit Agreement was amended as of June 28, 2011 to adjust certain covenants and financial ratios.

The Credit Agreement provides for an $80,000 secured term loan and a $30,000 secured revolving credit facility. The term loan was used to repay existing term loans provided for in the Prior Credit Agreement and to fund the acquisition of AVID. The revolving credit facility is used to finance the working capital needs and general corporate purposes of the Company and its subsidiaries and for permitted acquisitions. As of December 31, 2011 and February 3, 2012, $60,000 is outstanding on the term loan and $11,470 and $12,720 is outstanding on the revolving credit facility, respectively.

Borrowings under the Credit Agreement are collateralized by substantially all the assets of the Company and the agreement contains certain restrictive covenants, which, among other matters, impose limitations with respect to the incurrence of liens, guarantees, mergers, acquisitions, capital expenditures, specified sales of assets and prohibits the payment of dividends. The Company is also required to maintain various financial ratios which are measured quarterly. As of December 31, 2011, the Company is in compliance with all such covenants and financial ratios.

Contractual Obligations

Certain contractual cash obligations and other commercial commitments will impact our short and long-term liquidity. At December 31, 2011, such obligations and commitments are as follows:


	Total		Less than 1 Year		1 – 3 Years		4 – 5 Years		After 5 Years
Principal Payments of Long-Term Debt	$	71,470	$	16,000	$	43,470	$	12,000	$	—
Purchase Obligations		36,283		36,283		—		—		—
Capital Lease Obligations		30,153		1,481		3,052		3,175		22,445
Operating Leases		1,121		704		384		33		—
Defined Benefit Plan Payments		541		45		90		102		304


Total Contractual Obligations	$	139,568	$	54,513	$	46,996	$	15,310	$	22,749

The Company believes that the anticipated future cash flow from operations, coupled with its cash on hand and available funds under its revolving credit facility will be sufficient to meet working capital requirements. Although we have borrowing capacity on our revolving credit facility, cash on hand and anticipate future cash flows from operations, we may be limited in our ability to allocate funds for purposes such as potential acquisitions, capital expenditures, marketing, development and other general corporate purposes. In addition, we may be limited in our flexibility in planning for, or responding to, changing conditions in our business and our industry, making us more vulnerable to general economic downturns and adverse developments in our business.

Related Party Transactions

As part of the assets and liabilities acquired from the AVID acquisition, the Company assumed a capital lease obligation for the AVID facility located in Toano, VA. The facility, which includes a 185,000 square foot manufacturing and warehouse building and approximately 12 acres of land, is owned by Micpar Realty, LLC (“Micpar”). AVID’s founder and former CEO, is a part owner of Micpar and subsequent to the acquisition of AVID, was elected to the Company’s board of directors and entered into an employment agreement with the Company on August 27, 2010, which expired in August 2011.

The gross and net book value of the capital lease for the periods presented is as follows:

		December 31,			December 31,
	December 31,			March 31,
	2011			2011
Capital lease, gross	$	11,409		$	11,409
Less: Accumulated amortization		(819	)		(358	)

Capital lease, net	$	10,590		$	11,051

The amortization expense associated with the capital lease is included in our selling, general and administrative expenses and amounted to $154 and $461 during the three and nine months ended December 31, 2011.

As of December 31, 2011, the capital lease requires monthly payments of $122 with increases of 2% per annum. The lease contains provisions for an option to buy after three and five years and expires in March 2029. The effective rate on the capital lease obligation is 9.9%. Total lease payments required under the capital lease for the five-year period ending December 31, 2016 is $7,708.

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements, transactions, obligations or other relationships with unconsolidated entities that would be expected to have a material current or future effect upon our financial condition or results of operations.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed to interest rate change market risk with respect to its credit facility with a financial institution which is priced based on the alternate base rate of interest plus a spread of up to 2.50%, or at LIBOR rate plus a spread of up to 3.50%. The spread over the alternate base rate and LIBOR rates is determined based upon the Company’s performance with regard to agreed-upon financial ratios. The Company decides at its sole discretion as to whether borrowings will be at the alternate base rate or LIBOR. At December 31, 2011, $71,470 was outstanding under the credit facility. Changes in the alternate base rates or LIBOR rates during fiscal 2012 will have a positive or negative effect on the Company’s interest expense. Each 1% fluctuation in the interest rate will increase or decrease interest expense for the Company by approximately $715 on an annualized basis.

A significant portion of the Company’s raw materials are purchased from China. All such purchases are transacted in U.S. dollars. The Company’s financial results, therefore, could be impacted by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign countries in the procurement of such raw materials. To date, sales of the Company’s products outside the United States have not been significant.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act, as of the end of the period covered by this Report. Based upon that evaluation, the Company’s management concluded that, as of December 31, 2011, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

During the three months ended December 31, 2011, we have not made any changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

We continue to review, document and test our internal control over financial reporting and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business. These efforts may lead to various changes in our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

There are no material legal proceedings against the Company or in which any of its property is subject.

Item 1A.

Risk Factors

Additional Risk Factors

There have been no material changes to the Risk Factors disclosed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2011, other than the following:

We have recorded goodwill and other intangible assets as a result of acquisitions, and future business conditions could cause these assets to become impaired, requiring substantial write-downs that would reduce our operating income.

We are required to annually test our goodwill and intangible assets with indefinite lives to determine if impairment has occurred. If the testing performed indicates that impairment has occurred, we are required to record a non-cash impairment charge for the difference between the carrying value of the goodwill and other intangible assets and the fair value of the goodwill and other intangible assets in the period the determination is made. As of December 31, 2011, we assessed that the fair value of the Company was in excess of its carrying value by approximately 13% and concluded that there was no impairment.

Our testing is comprised of several methodologies, including; a discounted cash flow method, a guideline company method and a market capitalization method. This requires significant assumptions including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, the useful life over which cash flows will occur, determination of our weighted average cost of capital and the effect that changes in our stock price have on our market capitalization.

Changes in these estimates and assumptions, including the impact of changes in our stock price, could materially affect the determination of fair value and/or goodwill impairment. We will continue to monitor and evaluate the potential impact of changes in our estimates and assumptions and perform interim impairment testing if triggering events arise prior to our annual impairment testing.

Accordingly, it is possible that we could recognize an impairment charge in the future with respect to goodwill and/or other intangible assets, which would have an adverse effect on our consolidated financial condition and results of operations.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.

Defaults Upon Senior Securities

None

Item 4.

(Removed and Reserved)

Item 5.

Other Information

None

Item 6.

Exhibits and Reports on Form 8-K

(a)

Exhibits

31.1 and 31.2 – Certifications pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002

32.1 and 32.2 – Certifications pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101 – The following materials from our Quarterly Report on Form 10-Q for the quarter ended December 31, 2011, formatted in eXtensible Business Reporting Language (XBRL); (i) the Condensed Consolidated Balance Sheets (Unaudited), (ii) the Condensed Consolidated Statements of Operations (Unaudited), (iii) the Condensed Consolidated Statement of Changes in Stockholders’ Equity (Unaudited), (iv) the Condensed Consolidated Statements of Cash Flows (Unaudited) and (v) Notes to the Condensed Consolidated Financial Statements (Unaudited)

(b)

Reports on Form 8-K

Current Report on Form 8-K dated November 1, 2011, covering Item 5.03 – Amendments to Articles of Incorporation of Bylaws; Change in Fiscal Year and Item 5.05 – Amendments to the Company’s Code of Ethics

Current Report on Form 8-K dated February 1, 2012, covering Item 7.01 – Results of Operations and Financial Condition and Item 9.01 – Financial Statements and Exhibits

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company